Copyright © Inderes 2011 - present. All rights reserved.

Gabather

0.05

 

SEK

 

-1.58 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Read more
Market cap
11.76M SEK
Turnover
6.21K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
30/6
2025

General meeting '25

28/8
2025

Interim report Q2'25

27/11
2025

Interim report Q3'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...

Gabather
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.